Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Artifacts Summary
.... 14.1 Adaptation
.... 14.2 BaselineMeasureEvidence
.... 14.3 BaselineMeasureReport
.... 14.4 BaselineVariablesList
.... 14.5 BookCitation
.... 14.6 BookPartCitation
.... 14.7 CertaintyOfEvidence
.... 14.8 Classification
.... 14.9 CohortDefinition
.... 14.10 Comment
.... 14.11 ComparativeBaselineMeasureEvidence
.... 14.12 ComparativeEvidence
.... 14.13 ComparativeEvidenceReport
.... 14.14 ComparativeEvidenceReportExpanded
.... 14.15 ComparativeEvidenceReportSubject
.... 14.16 ComparativeEvidenceSynthesisReport
.... 14.17 ComparativeParticipantFlowEvidence
.... 14.18 ComparatorGroup
.... 14.19 ComparatorOnlyEvidence
.... 14.20 Comparison
.... 14.21 CompositeRating
.... 14.22 ConceptualCohortDefinition
.... 14.23 ConceptualComparatorDefinition
.... 14.24 ConceptualExposureDefinition
.... 14.25 DatabaseCitation
.... 14.26 DatabaseEntryCitation
.... 14.27 DatasetCitation
.... 14.28 DateAsRating
.... 14.29 DichotomousIntendedOutcome
.... 14.30 EndpointAnalysisPlan
.... 14.31 EvidenceAssessment
.... 14.32 EvidenceList
.... 14.33 EvidenceReport
.... 14.34 EvidenceReportPackage
.... 14.35 EvidenceReportSubject
.... 14.36 EvidenceSynthesisEvidence
.... 14.37 ExposureGroup
.... 14.38 GroupAssignment
.... 14.39 GroupR6
.... 14.40 Guideline
.... 14.41 InterventionOnlyEvidence
.... 14.42 JournalArticleCitation
.... 14.43 M11Report
.... 14.44 MetaanalysisEligibilityCriteria
.... 14.45 MetaanalysisOutcomeDefinition
.... 14.46 MetaanalysisStudyGroup
.... 14.47 NetEffectContribution
.... 14.48 NetEffectContributionList
.... 14.49 NetEffectContributions
.... 14.50 NetEffectEstimate
.... 14.51 NonComparativeEvidence
.... 14.52 OutcomeDefinition
.... 14.53 OutcomeImportance
.... 14.54 OutcomeList
.... 14.55 OutcomeMeasureReport
.... 14.56 OutcomeVariablesList
.... 14.57 ParticipantFlowEvidence
.... 14.58 ParticipantFlowEvidenceVariable
.... 14.59 ParticipantFlowReasonEvidenceVariable
.... 14.60 ParticipantFlowReport
.... 14.61 ParticipantFlowVariablesList
.... 14.62 PreprintCitation
.... 14.63 Rating
.... 14.64 Recommendation
.... 14.65 RecommendationAction
.... 14.66 RecommendationEligibilityCriteria
.... 14.67 RecommendationJustification
.... 14.68 RecommendationPlan
.... 14.69 RecommendationRating
.... 14.70 ResearchStudyDataDictionary
.... 14.71 ResearchStudySupport
.... 14.72 RiskOfBias
.... 14.73 SearchResults
.... 14.74 SearchStrategy
.... 14.75 SingleStudyEvidence
.... 14.76 SoaPlanDefinition
.... 14.77 SoftwareCitation
.... 14.78 StatisticModel
.... 14.79 StudyDesign
.... 14.80 StudyEligibilityCriteria
.... 14.81 StudyGroup
.... 14.82 StudyRegistryRecord
.... 14.83 SummaryOfFindings
.... 14.84 SummaryOfNetEffect
.... 14.85 SystematicReview
.... 14.86 SystematicReviewEligibilityCriteria
.... 14.87 SystematicReviewExcludedStudies
.... 14.88 SystematicReviewIncludedStudies
.... 14.89 VariableDefinition
.... 14.90 WebPageCitation
.... 14.91 ArtifactAssessmentCompared
.... 14.92 ArtifactAssessmentDateAsRating
.... 14.93 ArtifactPublicationStatus
.... 14.94 CharacteristicTiming
.... 14.95 CiteAs
.... 14.96 EvidenceVariableHandlingDetail
.... 14.97 GuidelineRegistration
.... 14.98 NumberAnalyzed
.... 14.99 RelatesTo
.... 14.100 RelatesToClassifier
.... 14.101 RelatesToWithQuotation
.... 14.102 RelativeOutcomeImportance
.... 14.103 ResearchStudyExcludedStudy
.... 14.104 ResearchStudyIncludedStudy
.... 14.105 ResearchStudyIsLowInterventionTrial
.... 14.106 ResearchStudyNumberOfStudiesIdentified
.... 14.107 ResearchStudyNumberOfStudiesIncluded
.... 14.108 ResearchStudySaeReportingMethod
.... 14.109 ResearchStudySearchStrategy
.... 14.110 ResearchStudySponsorConfidentialityStatement
.... 14.111 ResearchStudyStudyAmendment
.... 14.112 ResearchStudySystematicReviewEligibilityCriteria
.... 14.113 StatisticModelExpression
.... 14.114 StatisticModelIncludeIf
.... 14.115 EBMonFHIR Profile Name Value Set
.... 14.116 Evidence Rating System Classifier Codes Value Set
.... 14.117 Recommendation Justification Classifier Codes Value Set
.... 14.118 Research Study Document Types Value Set
.... 14.119 Search Strategy Characteristic Value Set
.... 14.120 EBMonFHIR Profile Name Code System
.... 14.121 Evidence Rating System Classifier Code System
.... 14.122 Research Study Document Types Code System
.... 14.123 Search Strategy Characteristic Code System
.... 14.124 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 14.125 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.126 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 14.127 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 14.128 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 14.129 179899
.... 14.130 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 14.131 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 14.132 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 14.133 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 14.134 19967827 Wonder woman was Argentine and her real name was Evita.
.... 14.135 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 14.136 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 14.137 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 14.138 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 14.139 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 14.140 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 14.141 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 14.142 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 14.143 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 14.144 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 14.145 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 14.146 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 14.147 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 14.148 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 14.149 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 14.150 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 14.151 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 14.152 27979893 6. Glycemic Targets.
.... 14.153 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 14.154 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 14.155 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 14.156 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 14.157 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 14.158 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 14.159 30467172 Finding my inner Wonder Woman.
.... 14.160 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.161 34871555 What Can Wonder Woman Teach Radiologists?
.... 14.162 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 14.163 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 14.164 367832
.... 14.165 367833
.... 14.166 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 14.167 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 14.168 399870
.... 14.169 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 14.170 A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus
.... 14.171 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 14.172 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.173 Add-on Amlodipine at 6 weeks
.... 14.174 Adults with diabetes mellitus type 2
.... 14.175 Adults with type 2 diabetes and CVD and CKD
.... 14.176 Adults with type 2 diabetes and established CVD (but no CKD)
.... 14.177 Adverse event free and hypertension control
.... 14.178 Adverse event free and hypertension control at 12 weeks
.... 14.179 Adverse Events Report for NCT03640312
.... 14.180 Age
.... 14.181 Age with comparator
.... 14.182 Age with intervention
.... 14.183 Aircraft Type
.... 14.184 Aircraft Type with comparator
.... 14.185 Aircraft Type with intervention
.... 14.186 Altitude
.... 14.187 Altitude comparing intervention vs. comparator
.... 14.188 Altitude for enrolled group
.... 14.189 Altitude for screened group
.... 14.190 Altitude with comparator
.... 14.191 Altitude with intervention
.... 14.192 Analyzed Group in PARACHUTE Trial
.... 14.193 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 14.194 Baseline Characteristics Report for NCT03640312
.... 14.195 Baseline Characteristics Report for QUARTET Trial
.... 14.196 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.197 Baseline Measures List for PARACHUTE Trial
.... 14.198 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 14.199 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 14.200 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 14.201 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 14.202 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.203 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 14.204 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.205 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.206 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 14.207 Candesartan 8 mg once daily
.... 14.208 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.209 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 14.210 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.211 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.212 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.213 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.214 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.215 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 14.216 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.217 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.218 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.219 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.220 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.221 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.222 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.223 Citation for EBMonFHIR Implementation Guide
.... 14.224 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.225 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 14.226 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.227 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 14.228 Comparative Evidence Report for QUARTET USA Trial
.... 14.229 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.230 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.231 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.232 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 14.233 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.234 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.235 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.236 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.237 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.238 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 14.239 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 14.240 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 14.241 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 14.242 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 14.243 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 14.244 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 14.245 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 14.246 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 14.247 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 14.248 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 14.249 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 14.250 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 14.251 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 14.252 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 14.253 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.254 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.255 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.256 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.257 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 14.258 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.259 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 14.260 ComparatorDefinition: Standard care
.... 14.261 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.262 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.263 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 14.264 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 14.265 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.266 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.267 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.268 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.269 Composite Rating of FOI 153881 for Project FOI 112280
.... 14.270 Computable_Publishing_LLC
.... 14.271 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 14.272 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.273 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.274 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.275 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.276 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 14.277 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 14.278 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 14.279 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 14.280 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 14.281 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 14.282 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 14.283 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 14.284 ConceptualCohortDefinition: Nonfatal stroke
.... 14.285 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter
.... 14.286 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter with Ranges
.... 14.287 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 14.288 ConceptualCohortDefinition: Severe obesity
.... 14.289 ConceptualCohortDefinition: T1DM or T2DM
.... 14.290 ConceptualCohortDefinition: T1DM-specific criteria
.... 14.291 ConceptualCohortDefinition: T2DM-specific criteria
.... 14.292 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 14.293 ConceptualCohortDefinition_Cardiovascular_event
.... 14.294 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.295 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 14.296 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.297 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 14.298 COVID_19PneumoniaHospitalizedAdult
.... 14.299 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.300 CTIS2024-516402-32-00 Eligibility Criteria
.... 14.301 CTIS2024-516402-32-00 Primary Outcome 1
.... 14.302 CTIS2024-516402-32-00 Secondary Outcome 1
.... 14.303 CTIS2024-516402-32-00 Secondary Outcome 2
.... 14.304 CTIS2024-516402-32-00 Secondary Outcome 3
.... 14.305 CTIS2024-516402-32-00 Secondary Outcome 4
.... 14.306 CTIS2024-516402-32-00 Secondary Outcome 5
.... 14.307 CTIS2024-516402-32-00 Secondary Outcome 6
.... 14.308 CTIS2024-516402-32-00 Secondary Outcome 7
.... 14.309 CTIS2024-516402-32-00 Secondary Outcome 8
.... 14.310 DatabaseCitation: Citation for FEvIR Platform
.... 14.311 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.312 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 14.313 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 14.314 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 14.315 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 14.316 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 14.317 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 14.318 declined randomization in PARACHUTE Study
.... 14.319 deemed unsuitable by investigator in PARACHUTE Trial
.... 14.320 Delany-Moretlwe 2022 clinical trial
.... 14.321 Diabetes treatment medication
.... 14.322 Diastolic blood pressure at 12 weeks
.... 14.323 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 14.324 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 14.325 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 14.326 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 14.327 Eligibility criteria for NMA_Diabetes
.... 14.328 Eligibility Criteria for QUARTET USA Trial
.... 14.329 Eli_Lilly_Japan_K_K
.... 14.330 Enrolled Group for QUARTET USA Trial
.... 14.331 Enrolled Group PARACHUTE Trial
.... 14.332 Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie
.... 14.333 Ethnic Group
.... 14.334 Ethnic Group with comparator
.... 14.335 Ethnic Group with intervention
.... 14.336 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 14.337 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.338 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.339 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 14.340 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 14.341 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.342 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.343 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 14.344 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.345 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.346 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.347 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.348 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.349 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.350 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.351 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 14.352 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.353 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.354 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.355 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 14.356 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.357 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.358 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.359 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.360 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.361 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 14.362 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.363 EvidenceReportSectionCode Value Set
.... 14.364 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.365 EvidenceVariable Handling Extension Value Set
.... 14.366 EvidenceVariable: case_id
.... 14.367 EvidenceVariable: Patient id
.... 14.368 EvidenceVariable: Time of measurement
.... 14.369 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.370 Excluded from PARACHUTE Study
.... 14.371 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 14.372 ExposureVariable: Age (as continuous variable)
.... 14.373 ExposureVariable: Body Mass Index (as continuous variable)
.... 14.374 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 14.375 ExposureVariable: pht013093.v1.p1 RACE
.... 14.376 ExposureVariable: pht013093.v1.p1 SEX
.... 14.377 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 14.378 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 14.379 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 14.380 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 14.381 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 14.382 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 14.383 ExposureVariable: pht013094.v1.p1 Source_Type
.... 14.384 Family History of Parachute Use
.... 14.385 Family History of Parachute Use with comparator
.... 14.386 Family History of Parachute Use with intervention
.... 14.387 Frequent Flier
.... 14.388 Frequent Flier with comparator
.... 14.389 Frequent Flier with intervention
.... 14.390 GLP-1 RA Group in Adults with type 2 diabetes
.... 14.391 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 14.392 Glucagon Hydrochloride Solution (Active Comparator)
.... 14.393 Glucagon Nasal Powder (Experimental)
.... 14.394 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 14.395 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 14.396 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 14.397 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.398 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.399 GroupAssignment: GLP-1 RA vs. Standard care
.... 14.400 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 14.401 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 14.402 GroupAssignment: Non Participants vs. Enrolled Participants
.... 14.403 GroupAssignment: Quadpill vs. Candesartan
.... 14.404 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 14.405 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 14.406 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 14.407 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 14.408 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 14.409 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.410 Health Survey Score Total
.... 14.411 Health Survey Score Total comparing intervention vs. comparator
.... 14.412 Health Survey Score Total with comparator
.... 14.413 Health Survey Score Total with intervention
.... 14.414 Health Survey Score-Mental Health Subscore
.... 14.415 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 14.416 Health Survey Score-Mental Health Subscore with comparator
.... 14.417 Health Survey Score-Mental Health Subscore with intervention
.... 14.418 Health Survey Score-Physical Health Subscore
.... 14.419 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 14.420 Health Survey Score-Physical Health Subscore with comparator
.... 14.421 Health Survey Score-Physical Health Subscore with intervention
.... 14.422 Health-related Quality of Life (NCT03640312)
.... 14.423 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 14.424 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.425 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.426 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 14.427 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.428 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.429 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.430 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.431 Height
.... 14.432 Height with comparator
.... 14.433 Height with intervention
.... 14.434 High Blood Pressure Medication Value Set
.... 14.435 History of Acrophobia
.... 14.436 History of Acrophobia with comparator
.... 14.437 History of Acrophobia with intervention
.... 14.438 History of Broken Bones
.... 14.439 History of Broken Bones with comparator
.... 14.440 History of Broken Bones with intervention
.... 14.441 History of Parachute Use
.... 14.442 History of Parachute Use with comparator
.... 14.443 History of Parachute Use with intervention
.... 14.444 Hypertension Control at 12 weeks
.... 14.445 ICD-10-GM Terminale Codes
.... 14.446 IGBJ Protocol Narrative 1.3
.... 14.447 IGBJ Protocol Narrative 2.1
.... 14.448 IGBJ Protocol Narrative 5.1
.... 14.449 IGBJ Protocol Narrative 9
.... 14.450 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 14.451 Injury Severity Score 30 days after Impact with comparator
.... 14.452 Injury Severity Score 30 days after Impact with intervention
.... 14.453 Injury Severity Score on Impact comparing intervention vs. comparator
.... 14.454 Injury Severity Score on Impact with comparator
.... 14.455 Injury Severity Score on Impact with intervention
.... 14.456 International vs Domestic Flight
.... 14.457 International vs Domestic Flight with comparator
.... 14.458 International vs Domestic Flight with intervention
.... 14.459 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.460 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 14.461 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.462 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.463 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.464 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.465 Investigator
.... 14.466 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 14.467 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 14.468 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.469 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.470 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.471 Jumping from aircraft with empty backpack
.... 14.472 Jumping from aircraft with parachute
.... 14.473 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.474 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.475 M11 IGBJ Protocol Example Eligibility Criteria
.... 14.476 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 14.477 M11 Report Template Instructions
.... 14.478 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.479 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.480 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.481 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.482 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.483 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.484 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.485 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.486 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.487 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.488 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.489 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.490 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.491 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.492 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.493 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.494 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.495 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.496 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.497 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.498 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.499 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.500 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.501 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.502 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.503 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.504 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.505 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.506 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.507 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.508 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.509 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.510 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.511 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.512 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.513 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.514 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.515 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.516 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.517 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.518 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.519 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.520 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.521 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.522 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.523 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.524 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.525 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.526 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.527 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.528 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.529 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.530 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.531 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.532 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.533 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.534 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.535 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.536 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.537 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.538 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.539 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.540 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.541 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.542 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.543 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.544 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 14.545 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 14.546 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.547 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.548 Mean Change in Serum Creatinine (NCT03640312)
.... 14.549 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 14.550 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.551 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.552 Mean Change in Serum Potassium (NCT03640312)
.... 14.553 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 14.554 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.555 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.556 Mean Change in Serum Sodium (NCT03640312)
.... 14.557 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 14.558 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.559 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.560 Mean Diastolic Blood Pressure (NCT03640312)
.... 14.561 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.562 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.563 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.564 Mean Systolic Blood Pressure (NCT03640312)
.... 14.565 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.566 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.567 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.568 Median Age of Parachute Intervention Group
.... 14.569 Medication Adherence (NCT03640312)
.... 14.570 Medication Adherence at 12 weeks
.... 14.571 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 14.572 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.573 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.574 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.575 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.576 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 14.577 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.578 Mortality at 14 days
.... 14.579 NCT03421379 Eligibility Criteria
.... 14.580 NCT03640312 Eligibility Criteria
.... 14.581 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022
.... 14.582 NetEffectContribution: All-cause mortality for Example for GIN 2022
.... 14.583 NetEffectContribution: New onset depression for Example for GIN 2022
.... 14.584 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022
.... 14.585 NetEffectContribution: Remission of diabetes for Example for GIN 2022
.... 14.586 NetEffectContribution: Treatment with opioids for Example for GIN 2022
.... 14.587 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 14.588 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 14.589 NetEffectEstimate: Bariatric Surgery Example for GIN 2022
.... 14.590 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 14.591 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 14.592 NHANES LBXGLU Variable Definition Cohort Definition
.... 14.593 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 14.594 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 14.595 NHANES SEQN Respondent Sequence Number
.... 14.596 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 14.597 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 14.598 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 14.599 NT-proBNP Study Data Dictionary
.... 14.600 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 14.601 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 14.602 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.603 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.604 Organ support-free days
.... 14.605 Outcome Importance Rating 100 of All-cause mortality
.... 14.606 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 14.607 Outcome Importance Rating 5 of New onset depression
.... 14.608 Outcome Importance Rating 5 of Remission of diabetes
.... 14.609 Outcome Importance Rating 5 of Treatment with opioids
.... 14.610 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 14.611 Outcome Measure List for QUARTET USA Trial
.... 14.612 Outcome Measure Report for QUARTET USA Trial
.... 14.613 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.614 Outcome Measures Report for NCT03640312
.... 14.615 Outcome Variables List for PARACHUTE Trial
.... 14.616 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 14.617 Outcome: Death or Major Traumatic Injury on Impact
.... 14.618 Outcome: Injury Severity Score 30 days after Impact
.... 14.619 Outcome: Injury Severity Score on Impact
.... 14.620 OutcomeDefinition: Injury Severity Score on Impact
.... 14.621 OutcomeDefinition: All-cause mortality
.... 14.622 OutcomeDefinition: All-cause mortality
.... 14.623 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 14.624 OutcomeDefinition: Body weight
.... 14.625 OutcomeDefinition: Body weight
.... 14.626 OutcomeDefinition: Cardiovascular mortality
.... 14.627 OutcomeDefinition: Cardiovascular mortality
.... 14.628 OutcomeDefinition: Diabetes in remission
.... 14.629 OutcomeDefinition: Diabetic ketoacidosis
.... 14.630 OutcomeDefinition: End-stage kidney disease
.... 14.631 OutcomeDefinition: End-stage kidney disease
.... 14.632 OutcomeDefinition: Genital infection
.... 14.633 OutcomeDefinition: HbA1c at 12 months
.... 14.634 OutcomeDefinition: HbA1c at 24 months
.... 14.635 OutcomeDefinition: HbA1c at 36 months
.... 14.636 OutcomeDefinition: HbA1c at 6 months
.... 14.637 OutcomeDefinition: HbA1c at 60 months
.... 14.638 OutcomeDefinition: Health-related quality of life
.... 14.639 OutcomeDefinition: Health-related quality of life
.... 14.640 OutcomeDefinition: Heart failure
.... 14.641 OutcomeDefinition: Heart failure
.... 14.642 OutcomeDefinition: Mortality at 14 days
.... 14.643 OutcomeDefinition: New onset depression
.... 14.644 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.645 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.646 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 14.647 OutcomeDefinition: Nonfatal stroke
.... 14.648 OutcomeDefinition: Nonfatal stroke
.... 14.649 OutcomeDefinition: Serious hyperglycaemia
.... 14.650 OutcomeDefinition: Serious hyperglycaemia
.... 14.651 OutcomeDefinition: Severe gastrointestinal events
.... 14.652 OutcomeDefinition: Severe gastrointestinal events
.... 14.653 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.654 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.655 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 14.656 OutcomeVariable: HbA1c at 12 months
.... 14.657 OutcomeVariable: HbA1c at 24 months
.... 14.658 OutcomeVariable: HbA1c at 36 months
.... 14.659 OutcomeVariable: HbA1c at 6 months
.... 14.660 OutcomeVariable: HbA1c at 60 months
.... 14.661 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.662 OutcomeVariable: New onset depression
.... 14.663 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 14.664 OutcomeVariable: Remission of diabetes
.... 14.665 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.666 OutcomeVariable_Additional_GI_surgical_procedure
.... 14.667 OutcomeVariable_All_cause_mortality
.... 14.668 OutcomeVariable_Treatment_with_opioids
.... 14.669 PARACHUTE Trial baseline characteristics
.... 14.670 PARACHUTE Trial non participants
.... 14.671 PARACHUTE trial participant flow report
.... 14.672 PARACHUTE Trial Participants
.... 14.673 PARACHUTE Trial Participants assigned an empty backpack
.... 14.674 PARACHUTE trial participants assigned parachute
.... 14.675 PARACHUTE Trial Participants available for randomization
.... 14.676 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 14.677 PARACHUTE Trial Participants randomized into groups
.... 14.678 PARACHUTE Trial Participants randomized into groups for screened group
.... 14.679 PARACHUTE Trial Participants randomized into groups with comparator
.... 14.680 PARACHUTE Trial Participants randomized into groups with intervention
.... 14.681 PARACHUTE Trial Participants that completed 30 day follow up
.... 14.682 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 14.683 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 14.684 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 14.685 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 14.686 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 14.687 PARACHUTE Trial Participants that declined randomization
.... 14.688 PARACHUTE Trial Participants with no contact at 30 days
.... 14.689 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 14.690 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 14.691 PARACHUTE Trial Results
.... 14.692 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.693 Parachute vs Empty Backpack in PARACHUTE Trial
.... 14.694 Participant Flow Report for NCT03640312
.... 14.695 Participant Flow Report for QUARTET USA Trial
.... 14.696 Participant Flow Variables List for PARACHUTE Trial
.... 14.697 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 14.698 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 14.699 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 14.700 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 14.701 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 14.702 ParticipantFlowMeasure: Exclusion from analysis
.... 14.703 ParticipantFlowMeasure: Inclusion in analysis
.... 14.704 Participants Excluded from PARACHUTE Study
.... 14.705 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 14.706 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 14.707 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.708 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 14.709 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 14.710 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 14.711 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.712 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.713 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 14.714 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 14.715 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.716 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.717 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 14.718 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.719 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.720 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.721 Placebo
.... 14.722 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.723 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.724 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 14.725 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 14.726 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 14.727 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.728 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.729 Proportion of Patients With Hypertension Control (NCT03640312)
.... 14.730 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 14.731 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 14.732 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 14.733 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 14.734 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 14.735 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 14.736 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.737 Quadpill once daily
.... 14.738 QUARTET USA Trial Control Group
.... 14.739 QUARTET USA Trial Quadpill group
.... 14.740 randomized into groups for PARACHUTE Trial
.... 14.741 Rate of Adverse Events of Special Interest (NCT03640312)
.... 14.742 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 14.743 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.744 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.745 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 14.746 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 14.747 Reasons for exclusion from QUARTET USA Trial
.... 14.748 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 14.749 Recommendation Justification Code System
.... 14.750 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 14.751 Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.752 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 14.753 Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.754 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 14.755 Remdesivir
.... 14.756 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 14.757 Results Section for NCT03421379
.... 14.758 Results Section for NCT03640312
.... 14.759 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.760 Risk of Bias Assessment of PARACHUTE trial
.... 14.761 Risk Of Bias Type Value Set
.... 14.762 Screened Group PARACHUTE Trial
.... 14.763 Search Strategy for NMA_Diabetes
.... 14.764 SearchResults: PubMed search for Wonder Woman
.... 14.765 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 14.766 SearchStrategy: PubMed search for Wonder Woman
.... 14.767 Sex
.... 14.768 Sex with comparator
.... 14.769 Sex with intervention
.... 14.770 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.771 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 14.772 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 14.773 Spanish or English Value Set
.... 14.774 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.775 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 14.776 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 14.777 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 14.778 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.779 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 14.780 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 14.781 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 14.782 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 14.783 Summary of Findings - QUARTET USA Trial
.... 14.784 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.785 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.786 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.787 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.788 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.789 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.790 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.791 Systolic blood pressure at 12 weeks
.... 14.792 Time to integration of results in a recommendation
.... 14.793 VariableDefinition: Comparator
.... 14.794 VariableDefinition: Condition(s)
.... 14.795 VariableDefinition: Date of birth
.... 14.796 VariableDefinition: Date of measurement
.... 14.797 VariableDefinition: Gender
.... 14.798 VariableDefinition: NTproBNP
.... 14.799 VariableDefinition: Unit
.... 14.800 Velocity
.... 14.801 Velocity comparing intervention vs. comparator
.... 14.802 Velocity for enrolled group
.... 14.803 Velocity for non participant group
.... 14.804 Velocity with comparator
.... 14.805 Velocity with intervention
.... 14.806 WebPageCitation: A HEvKA Update Summary
.... 14.807 Weight
.... 14.808 Weight with comparator
.... 14.809 Weight with intervention